PLYMOUTH MEETING – November 03, 2026 -- INOVIO (NASDAQ: INO) will present its INO-D001 program for Hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy (NTGT) Workshop in Montreal on Thursday, Nov. 12, extending its DNA medicine work beyond HPV-related diseases, cancer and infectious diseases.